Treatment of Selinexor in Combination With Clarithromycin Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

  • End date
    Nov 28, 2024
  • participants needed
  • sponsor
    Weill Medical College of Cornell University
Updated on 28 November 2021
measurable disease
refractory multiple myeloma


The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.

Condition Refractory Multiple Myeloma, multiple myeloma (mm), Lymphoproliferative Disorder, Lymphoproliferative disorders, Multiple Myeloma
Treatment Pomalidomide, Dexamethasone, clarithromycin, Selinexor
Clinical Study IdentifierNCT04843579
SponsorWeill Medical College of Cornell University
Last Modified on28 November 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent in accordance with federal, local, and institutional guidelines
Age 18 and <75 years at the time of informed consent
Confirmed diagnosis of multiple myeloma
Symptomatic multiple myeloma per IMWG guidelines
Measurable disease as defined by at least one of the following: a. Serum M-protein 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA, and/or b. Urinary M-protein excretion at least 200 mg/24 hours, and/or c. Serum FLC 100 mg/L, provided that FLC ratio is abnormal, and/or d. If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement (e.g., for IgA MM), then quantitative Ig levels by nephelometry or turbidimetry are acceptable
Relapsed and refractory multiple myeloma with documented evidence of PD after achieving at least SD for 1 cycle during a previous MM regimen (i.e., relapsed MM), and 25% response (i.e., patients never achieved MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM)
Previously received one to four prior lines of therapy and be pomalidomide-nave

Exclusion Criteria

Documented active systemic light chain amyloidosis
Active plasma cell leukemia
Eastern Cooperative Oncology Group (ECOG) Performance Status greater than 2
Persistent non-hematological toxicity (except for peripheral neuropathy) from a prior treatment which has not resolved to at least Grade 2 or better by Cycle 1 Day 1 (C1D1)
Severe hepatic dysfunction with either: a. Total bilirubin > 2x ULN (> 3x ULN in subjects with Gilbert's syndrome [hereditary indirect hyperbilirubinemia]), and/or b. AST and/or ALT > 2.5x ULN
Severe renal dysfunction with an estimated creatinine clearance of < 15 mL/min calculated using the Cockcroft and Gault formula
Impaired hematopoietic function with either: a. White blood cell count < 1,500/mm3, and/or b. Absolute neutrophil count < 1000/mm3, and/or c. Hemoglobin < 8.0 g/dL, and/or d. Platelet count < 100,000/mm3 (for patients in whom 50% of bone marrow nucleated cells are plasma cells, platelets 75,000/mm3 are acceptable)
Blood (or blood product) transfusions or blood growth factors within 7 days of C1D1. Use of hematopoietic growth factor support is acceptable, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim). However, patients must be platelet transfusion independent for > 1 week in order to be enrolled in the study
Radiation, chemotherapy or immunotherapy, or any other anticancer therapy within 2 weeks prior to C1D1, or radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures, as well as for pain management
Patients with history of spinal cord compression with residual paraplegia
Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1
Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1
Active graft versus host disease after allogeneic stem cell transplantation
Life expectancy < 3 months
Major surgery within 4 weeks prior to C1D1
Active, unstable cardiovascular function with either: a. Symptomatic ischemia, b. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), c. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class 3, d. Myocardial infarction (MI) within 6 months prior to C1D1, or e. Screening 12-lead ECG showing a baseline QT interval as corrected by Bazett's formula (QTc) > 470 msec
Uncontrolled active hypertension
Venous thromboembolism within 6 months prior to C1D1 or a known inherited thrombophilia
Inability to receive either prophylactic or therapeutic anticoagulation as determined appropriate by the Investigator
Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to C1D1
Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment
Currently pregnant or breastfeeding. Lactating females must agree not to breast feed while receiving selinexor, pomalidomide and/or clarithromycin
A serious psychiatric or medical condition which, in the opinion of the Investigator, could interfere with treatment
Hypersensitivity or contraindication to selinexor, pomalidomide, dexamethasone and/or clarithromycin
Prior exposure to a SINE compound, including selinexor
Concomitant use of any strong CYP3A4 and/or CYP1A2 inhibitors (see Appendix 1)
Unable to obtain commercial clarithromycin, pomalidomide and dexamethasone through a regular and/or specialty pharmacy
Unable or unwilling to register into the mandatory POMALYST REMSTM program and comply with its requirements
Male and female patients unwilling or unable to use effective methods of contraception throughout the study and for three months following the last dose. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Note that female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at Screening and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note